{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:34:05Z","timestamp":1793644445994,"version":"4.5.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.imlet.2025.107025","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T19:14:53Z","timestamp":1744658093000},"page":"107025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A novel MF59 and CpG1018 adjuvant combination enhances the humoral and cellular immune responses against a truncated varicella-zoster viral glycoprotein E"],"prefix":"10.1016","volume":"275","author":[{"given":"Jing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcai","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.imlet.2025.107025_bib0001","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1080\/21645515.2018.1560918","article-title":"Immune Responses to Zoster Vaccines","volume":"15","author":"Levin","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"issue":"5","key":"10.1016\/j.imlet.2025.107025_bib0002","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3390\/pharmaceutics14050973","article-title":"Ionizable lipid nanoparticles enhanced the synergistic adjuvant effect of Cpg Odns and Qs21 in a varicella zoster virus glycoprotein E subunit vaccine","volume":"14","author":"Luan","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.imlet.2025.107025_bib0003","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jama.2010.1983","article-title":"Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease","volume":"305","author":"Tseng","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.imlet.2025.107025_bib0004","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/v14020192","article-title":"A review of clinical manifestations and management","volume":"14","author":"Patil","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.imlet.2025.107025_bib0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41541-023-00757-0","article-title":"Healthy ageing: herpes zoster infection and the role of zoster vaccination","volume":"8","author":"Curran","year":"2023","journal-title":"npj Vaccines"},{"issue":"5","key":"10.1016\/j.imlet.2025.107025_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13344","article-title":"Senescence-associated \u0392-galactosidase reveals the abundance of senescent Cd8+ T cells in aging humans","volume":"20","author":"Mart\u00ednez-Zamudio","year":"2021","journal-title":"Aging Cell"},{"issue":"1","key":"10.1016\/j.imlet.2025.107025_bib0007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: emerging concepts in aging of the immune system","volume":"19","author":"Nikolich-\u017dugich","year":"2018","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.imlet.2025.107025_bib0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ni1033","article-title":"Age-related changes in lymphocyte development and function","volume":"5","author":"Linton","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.imlet.2025.107025_bib0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.imlet.2025.107025_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076321","article-title":"Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records","volume":"383","author":"Klein","year":"2023","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.imlet.2025.107025_bib0011","doi-asserted-by":"crossref","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","article-title":"G. Zoster-049 study, long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.imlet.2025.107025_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978203","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: a systematic review and network meta-analysis","volume":"13","author":"Xia","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.imlet.2025.107025_bib0013","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cid\/ciz770","article-title":"Adjuvanted recombinant glycoprotein E herpes zoster vaccine","volume":"70","author":"Levin","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.imlet.2025.107025_bib0014","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3344\/kjp.2020.33.3.201","article-title":"Recombinant zoster vaccine (Shingrix≪Sup≫&Reg;≪\/Sup≫): a new option for the prevention of herpes zoster and postherpetic neuralgia","volume":"33","author":"Singh","year":"2020","journal-title":"Korea. J. Pain"},{"issue":"Supplement_4","key":"10.1016\/j.imlet.2025.107025_bib0015","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","article-title":"Herpes Zoster Vaccines","volume":"224","author":"Harbecke","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.imlet.2025.107025_bib0016","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/viro.2002.1556","article-title":"The requirement of varicella zoster virus glycoprotein E (Ge) for viral replication and effects of glycoprotein I on Ge in melanoma cells","volume":"304","author":"Mo","year":"2002","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.imlet.2025.107025_bib0017","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s40588-016-0044-4","article-title":"Varicella-zoster virus glycoproteins: entry, replication, and pathogenesis","volume":"3","author":"Oliver","year":"2016","journal-title":"Curr. Clin. Microbiol. Rep."},{"issue":"3","key":"10.1016\/j.imlet.2025.107025_bib0018","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2249.2008.03633.x","article-title":"Varicella zoster virus glycoprotein E-specific Cd4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors","volume":"152","author":"Malavige","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"24","key":"10.1016\/j.imlet.2025.107025_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01641-20","article-title":"Identification and characterization of Cd4+ T cell epitopes after Shingrix vaccination","volume":"94","author":"Voic","year":"2020","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.imlet.2025.107025_bib0020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jiph.2022.05.014","article-title":"Different levels of humoral and cellular immunity to varicella-zoster virus in seropositive healthcare workers","volume":"15","author":"Kang","year":"2022","journal-title":"J. Infect. Public Health"},{"issue":"20","key":"10.1016\/j.imlet.2025.107025_bib0021","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a Tlr agonist and Qs21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.imlet.2025.107025_bib0022","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1073\/pnas.161293498","article-title":"Human Tlr9 confers responsiveness to bacterial DNA via species-specific Cpg motif recognition","volume":"98","author":"Bauer","year":"2001","journal-title":"Proceed. Natl. Acad. Sci."},{"issue":"48","key":"10.1016\/j.imlet.2025.107025_bib0023","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1016\/j.vaccine.2014.06.065","article-title":"Clinical evaluation of Cpg oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer","volume":"32","author":"Scheiermann","year":"2014","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.imlet.2025.107025_bib0024","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0264-410X(03)00045-8","article-title":"A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant","volume":"21","author":"Halperin","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.imlet.2025.107025_bib0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vaccine.2005.08.095","article-title":"Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults","volume":"24","author":"Halperin","year":"2006","journal-title":"Vaccine"},{"issue":"49","key":"10.1016\/j.imlet.2025.107025_bib0026","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1016\/j.vaccine.2022.10.045","article-title":"Safety, tolerability and immunogenicity of biological E's Corbevax\u2122 vaccine in children and adolescents: a prospective, randomised, double-blind, placebo controlled, phase-2\/3 study","volume":"40","author":"Thuluva","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2025.107025_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104217","article-title":"Evaluation of safety and immunogenicity of receptor-binding domain-based Covid-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1\/2 and phase-2 clinical trials","volume":"83","author":"Thuluva","year":"2022","journal-title":"eBioMedicine"},{"issue":"1","key":"10.1016\/j.imlet.2025.107025_bib0028","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.imlet.2025.107025_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24662","article-title":"Research progress on emulsion vaccine adjuvants","volume":"10","author":"Huang","year":"2024","journal-title":"Heliyon"},{"issue":"Pt 8","key":"10.1016\/j.imlet.2025.107025_bib0030","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1099\/vir.0.81849-0","article-title":"Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses","volume":"87","author":"Vajdy","year":"2006","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.imlet.2025.107025_bib0031","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.vaccine.2007.11.054","article-title":"Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice","volume":"26","author":"Wack","year":"2008","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.imlet.2025.107025_bib0032","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"As04, an aluminum salt- and Tlr4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity1","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2025.107025_bib0033","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41541-022-00472-2","article-title":"Adjuvanting a subunit Sars-Cov-2 vaccine with clinically relevant adjuvants induces durable protection in mice","volume":"7","author":"Grigoryan","year":"2022","journal-title":"npj Vaccine."},{"issue":"35","key":"10.1016\/j.imlet.2025.107025_bib0034","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1016\/j.vaccine.2022.07.030","article-title":"Cpg 1018\u00ae adjuvant enhances tdap immune responses against bordetella pertussis in mice","volume":"40","author":"DeJong","year":"2022","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.imlet.2025.107025_bib0035","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1080\/21645515.2019.1596710","article-title":"Rsv recombinant candidate vaccine G1f\/M2 with Cpg as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs","volume":"15","author":"Li","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.imlet.2025.107025_bib0036","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of Mf59\u00ae adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O'Hagan","year":"2013","journal-title":"Expert Rev. Vacc."},{"issue":"3","key":"10.1016\/j.imlet.2025.107025_bib0037","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41570-020-00244-3","article-title":"Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action","volume":"5","author":"Pifferi","year":"2021","journal-title":"Nat. Rev. Chem."},{"issue":"22","key":"10.1016\/j.imlet.2025.107025_bib0038","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Aging, immunity, and the varicella\u2013zoster virus","volume":"352","author":"Arvin","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.imlet.2025.107025_bib0039","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus\u2013specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.imlet.2025.107025_bib0040","series-title":"Varicella-Zoster Virus","first-page":"341","article-title":"Vzv T cell-mediated immunity","author":"Weinberg","year":"2010"},{"issue":"Supplement_2","key":"10.1016\/j.imlet.2025.107025_bib0041","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1086\/522123","article-title":"Humoral and cellular immunity to varicella-zoster virus: an overview","volume":"197","author":"Arvin","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"44","key":"10.1016\/j.imlet.2025.107025_bib0042","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"Vzv-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the Shez study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2025.107025_bib0043","series-title":"Vaccine Adjuvants: Methods and Protocols","first-page":"15","article-title":"Development of the Cpg adjuvant 1018: a case study","author":"Campbell","year":"2017"},{"issue":"12","key":"10.1016\/j.imlet.2025.107025_bib0044","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of Mf59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"issue":"4","key":"10.1016\/j.imlet.2025.107025_bib0045","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4161\/hv.19229","article-title":"Mf59 oil-in-water emulsion in combination with a synthetic Tlr4 agonist (E6020) is a potent adjuvant for a combination meningococcus vaccine","volume":"8","author":"Singh","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.imlet.2025.107025_bib0046","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41541-023-00714-x","article-title":"Protective antibody threshold of Rts,S\/As01 malaria vaccine correlates antigen and adjuvant dose in mouse model","volume":"8","author":"Genito","year":"2023","journal-title":"npj Vaccine."},{"key":"10.1016\/j.imlet.2025.107025_bib0047","series-title":"Vaccine Design: The Subunit and Adjuvant Approach","first-page":"277","article-title":"Mf59 design and evaluation of a safe and potent adjuvant for human vaccines","author":"Ott","year":"1995"},{"issue":"06","key":"10.1016\/j.imlet.2025.107025_bib0048","first-page":"566","article-title":"Influence of CpG oligodeoxynucleotide adjuvant on immune effect of rabies vaccine","volume":"30","author":"Yan","year":"2017","journal-title":"Chin. J. Biolog."},{"issue":"2","key":"10.1016\/j.imlet.2025.107025_bib0049","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/nat.2012.0340","article-title":"Cpg still rocks! update on an accidental drug","volume":"22","author":"Krieg","year":"2012","journal-title":"Nucl. Acid. Ther."},{"key":"10.1016\/j.imlet.2025.107025_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.590054","article-title":"Cpg adjuvant in allergen-specific immunotherapy: finding the sweet spot for the induction of immune tolerance","volume":"12","author":"Montamat","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2025.107025_bib0051","series-title":"Varicella-Zoster Virus","first-page":"309","article-title":"Simian varicella virus pathogenesis","author":"Mahalingam","year":"2010"},{"issue":"1","key":"10.1016\/j.imlet.2025.107025_bib0052","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.imbio.2018.09.002","article-title":"Are rats more human than mice?","volume":"224","author":"Wildner","year":"2019","journal-title":"Immunobiology"},{"issue":"7","key":"10.1016\/j.imlet.2025.107025_bib0053","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00335-012-9399-x","article-title":"Identification of polymorphisms in genes of the immune system in cynomolgus macaques","volume":"23","author":"Wu","year":"2012","journal-title":"Mammal. Genom."},{"issue":"7","key":"10.1016\/j.imlet.2025.107025_bib0054","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2160158","article-title":"Safety and immunogenicity of a combined dtacp-sipv-Hib vaccine in animal models","volume":"18","author":"Zhang","year":"2022","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247825000586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247825000586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:04:57Z","timestamp":1762250697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247825000586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":54,"alternative-id":["S0165247825000586"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2025.107025","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel MF59 and CpG1018 adjuvant combination enhances the humoral and cellular immune responses against a truncated varicella-zoster viral glycoprotein E","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2025.107025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Immunological Societies. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107025"}}